Acute retinal necrosis following dexamethasone intravitreal implant (Ozurdex®) administration in an immunocompetent adult with a history of HSV encephalitis: a case report

BACKGROUND: Dexamethasone intravitreal implants (0.7 mg) (Ozurdex®, Allergan Inc., Madison, NJ) are FDA approved for managing macular oedema (ME) of retinal vein occlusion (RVO). The major complications associated with intravitreal Ozurdex® implant include increased intraocular pressure and cataract...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhi-Yong, Liu, Xiu-Yun, Jiang, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310153/
https://www.ncbi.nlm.nih.gov/pubmed/32571253
http://dx.doi.org/10.1186/s12886-020-01514-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310153/
https://www.ncbi.nlm.nih.gov/pubmed/32571253
http://dx.doi.org/10.1186/s12886-020-01514-w

Ejemplares similares